Tarsier Pharma
Tarsier Pharma47
About
What does Tarsier Pharma do?
Tarsier Pharma is a late clinical-stage company developing bio-inspired medical solutions for autoimmune and inflammatory ocular diseases. Their breakthrough platform technology, Dazdotuftide (TRS), aims to re-engineer the immune system to treat conditions like uveitis, with a pipeline including eye drops and intravitreal injections. They serve patients suffering from blinding ocular diseases and provide information for healthcare providers and investors.
What is Tarsier Pharma's revenue?
StartupHub estimates Tarsier Pharma's annual revenue at $2.1M (range $1.2M to $3.1M, 66% confidence), based on comparable companies in the sector.
What is Tarsier Pharma's valuation?
StartupHub estimates Tarsier Pharma's effective valuation at $18.5M (range $12.5M to $30.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Tarsier Pharma raised?
Tarsier Pharma has raised a total of $5M in funding. The most recent round on record is Series B.
Where is Tarsier Pharma headquartered?
Tarsier Pharma is headquartered in Tel Aviv, Israel.
When was Tarsier Pharma founded?
Tarsier Pharma was founded in 2016.
What industry does Tarsier Pharma operate in?
Tarsier Pharma operates in Healthcare, Disease Treatment, Vision Impairment, Biotech, MedTech, HealthTech.
How many employees does Tarsier Pharma have?
Tarsier Pharma has approximately 12 people on record.
No comments yet. Be the first to share your take.